What is RESTART?
RESTART is a randomised controlled trial for adults surviving spontaneous intracerebral haemorrhage who had taken an antithrombotic drug (i.e. anticoagulant or antiplatelet medication) for the prevention of vaso-occlusive disease before the ICH.
RESTART is testing whether a policy of starting antiplatelet drugs (one or more of aspirin, clopidogrel, or dipyridamole, chosen at investigator's discretion) results in a beneficial net reduction of all serious vascular events over two years compared with a policy of avoiding antiplatelet drugs.
RESTART began recruitment in the United Kingdom in May 2013.
Who is running RESTART?
RESTART is run by a team from the University of Edinburgh, in collaboration with researchers at the University of Dundee, the University of Newcastle-upon-Tyne, and University College London.
RESTART is overseen by a Steering Committee led by an independent chairperson, with representation from the British Heart Foundation.
RESTART accumulating data is overseen by a completely independent Data Monitoring Committee.